Seer, Inc. Class A Common Stock
SEERSeer, Inc. Class A (SEER) is a biotechnology company focused on developing advanced proteomics technologies to enable detailed analysis of proteins in biological samples. Its platform aims to facilitate breakthroughs in drug discovery, diagnostics, and research by providing high-throughput, precise, and scalable protein measurement solutions.
Company News
Seer, Inc. filed an investor presentation ahead of its July 28, 2026 Annual Meeting, highlighting progress against strategic goals including 62% CAGR in installed base growth, 36% decrease in annual cash burn since 2022, and a robust innovation pipeline. The company's Board unanimously recommends voting for its seven director nominees and opposes...
Seer, Inc. announced it has received an unsolicited acquisition proposal from Bradley L. Radoff and Michael Torok (Radoff-JEC Group) to acquire all outstanding Class A common stock for $2.25 per share in cash plus a contingent value right. The Radoff-JEC Group has also nominated three director candidates for the 2026 Annual Meeting. Seer's Board ...
Seer, Inc. announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference with over a dozen scientific presentations showcasing how its Proteograph Product Suite enables deep, scalable proteomics research across cardiovascular disease, neurodegeneration, aging biology, and oncology. The company will feature a...
Seer presented multiple scientific studies at HUPO 2025, demonstrating how their Proteograph platform enables deep proteomics research across cardiovascular, aging, and cancer biology, showcasing the technology's potential for population-scale discovery and clinical translation.
The next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.
